China Pharma Holdings, Inc. — Q1 2022 Form 10-Q
Business and period: The company develops, manufactures and markets human pharmaceutical products in China. Its unaudited results cover the three months ended March 31, 2022, compared with the same period in 2021. All operations are in the PRC; revenue is denominated in RMB.
Key financial results
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $1.604 million | $2.358 million; down 32.0% |
| Cost of revenue | $1.773 million; 110.6% of revenue | $2.086 million; 88.4% of revenue |
| Gross profit (loss) / margin | $(0.169) million; (10.6%) | $0.273 million; 11.6% |
| Operating loss | $(0.912) million | $(0.696) million |
| Net loss | $(1.029) million | $(0.767) million |
| Loss per share, basic and diluted | $(0.02) | $(0.02) |
| Operating cash flow | $(0.879) million | $(0.277) million |
| Cash and cash equivalents, March 31 | $3.715 million | $4.859 million at December 31, 2021 |
Operating expenses were $0.742 million, down from $0.969 million. Selling expense and R&D expense declined, while G&A expense rose to $0.514 million from $0.409 million. Interest expense increased to $0.124 million from $0.071 million. Comprehensive loss was $0.978 million, including a $0.052 million foreign-currency translation gain.
Balance sheet, debt and liquidity
- Total assets were $21.043 million and total liabilities were $15.703 million at March 31, 2022. Current assets of $8.165 million were below current liabilities of $9.903 million.
- Debt included $4.300 million of current lines of credit and a $4.950 million convertible, redeemable note. Related-party borrowings were $2.557 million. The company reported no non-current lines of credit.
- The $5.25 million original-principal convertible note was issued for $5.0 million in November 2021. During Q1, $0.3 million of principal was redeemed through issuance of 960,414 shares. The note’s conversion/redemption provisions can result in further share issuance and dilution.
- Cash declined by $1.144 million during the quarter. Investing cash outflow was $0.001 million and financing cash outflow was $0.276 million. The company said its $3.7 million cash balance was held in its Chinese subsidiary and not expected to be available for dividends or other payments to the parent or shareholders.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. It cited recurring operating losses and debt-service and operating costs. Management plans include improving advance-payment sales and collections, exploring nutrition-product opportunities, and potentially using fixed assets as collateral; it said plans were not finalized and substantial doubt remains.
Material changes and management commentary
- Revenue fell across all reported product categories. Anti-viral/infection/respiratory sales declined to $1.05 million from $1.50 million, primarily due to centralized-procurement price and volume pressure on products including Cefaclor Dispersible Tablet and Roxithromycin.
- Management attributed lower sales to centralized procurement price reductions and COVID-related quarantine and drug-sales controls in China. Lower revenue, with fixed costs not declining proportionately, drove the shift from gross profit to gross loss.
- Management described generic-drug consistency evaluations and centralized procurement as ongoing industry challenges. One product passed biological-equivalence testing in March 2021, and an application was submitted to the NMPA at the end of 2021. No new formula approvals were obtained in Q1 2022.
- The company is exploring comprehensive healthcare and nutrition products, but provided no quantified revenue or earnings guidance.
Risks, contingencies and unusual items
- Net trade receivables were $0.419 million, against an allowance for doubtful accounts of $18.385 million. The filing says 97.62% of receivables were more than 720 days old. Three customers represented 53.0%, 11.4% and 10.4% of receivables; two suppliers represented 29.2% and 28.4% of raw-material purchases.
- Lines of credit are due during 2022, including $4.300 million reported as current. Management said it did not expect refinancing difficulties, but noted there can be no assurance of future financing or continued related-party support.
- The company is exposed to PRC policy, economic, regulatory and currency risks. RMB conversion and remittance abroad are subject to government controls. COVID-19 resurgences may disrupt suppliers, customers, distribution or operations.
- Disclosure controls were deemed ineffective at March 31, 2022 because of a material weakness involving insufficient personnel knowledgeable in U.S. GAAP financial reporting. Management nevertheless concluded the interim statements were fairly stated in all material respects.
- The filing reports no off-balance-sheet arrangements. It identifies no income tax provision for the quarter and notes that approximately $4.4 million of PRC tax-loss carryforwards expire in December 2022.
Important facts for investors to verify
- Progress and actual results of plans to address the going-concern uncertainty, including financing, refinancing and related-party support.
- Convertible-note redemption terms, remaining balance, potential share issuance and resulting dilution.
- Receivable collectability, the very old receivables balance and customer concentration.
- Whether sales volumes and margins stabilize amid centralized procurement, COVID-related disruption and product-consistency requirements.
- The filing gives two different Q1 CEO-advance amounts: $1,202,472 in the liquidity discussion and $1,202,872 in a related-party note; verify the correct balance.
- Remediation of the disclosed financial-reporting control weakness and any subsequent improvement.